Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins
Immunotherapy · 2024
DOI: 10.2217/imt-2023-0165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, 2024. Verfasst von Sofia Vasilakaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, National & Kapodistrian University of Athens, Panepistimiopolis, Athens, 15771, Greece. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Models, Molecular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Aim
To compare the protein-protein interactions of antibodies targeting PD-1 and its ligand (PD-L1) with their targets in an attempt to explain the antibodies' binding affinity. Materials & methods: The structural features of complexes between pembrolizumab, nivolumab, durvalumab, atezolizumab, avelumab and PD-1/PD-L1 are described, with the use of software and based on crystallographic data.
Results
Pembrolizumab has more structural features, including the number and type of the bonds and total binding surface area, which could rationalize its different clinical behavior compared with nivolumab. Similarly, protein-protein interactions with PD-L1 differ among durvalumab, atezolizumab and avelumab.
Conclusion
Differential protein-protein interactions between antibodies and PD-1/PD-L1 may indicate differential clinical activity; however, further research is needed to provide evidence. This study looked at different immunotherapy drugs used to treat cancer. These drugs bind to two different proteins, called PD-1 and PD-L1, that are part of our immune system. These proteins usually act as brakes in our immune system. The drugs block the brakes, which boosts the immune system and improves the immune defense against cancer. Using computer images, the authors compared how each drug binds to PD-1/PD-L1. The results showed that these drugs bind to PD-1 and PD-L1 with different chemical bonds. These bonds can be smaller or larger depending on the drug. The drugs' different chemical bonds with PD-1/PD-L1 might show that they do not act exactly the same when they are given to patients. However, further studies are needed for more information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Department, National & Kapodistrian University of Athens, Panepistimiopolis, Athens, 15771, Greece.
- Oncology Unit, Third Department of Medicine, Sotiria General Hospital, 152 Mesogeion Avenue, Athens, 11527, Greece.
ORCID-Profile: Georgia Gomatou, Elias Kotteas
Zitieren
APA
Vasilakaki, S., Vathiotis, I., Panagiotou, E., Dimakakos, E., Gomatou, G., & Kotteas, E. (2024). Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins. Immunotherapy. https://doi.org/10.2217/imt-2023-0165
Vancouver
Vasilakaki S, Vathiotis I, Panagiotou E, Dimakakos E, Gomatou G, Kotteas E. Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins. Immunotherapy. 2024. doi:10.2217/imt-2023-0165
BibTeX
@article{Vasilakaki2024,
author = {Vasilakaki, Sofia and Vathiotis, Ioannis and Panagiotou, Emmanouil and Dimakakos, Evangelos and Gomatou, Georgia and Kotteas, Elias},
title = {Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins},
journal = {Immunotherapy},
year = {2024},
doi = {10.2217/imt-2023-0165}
}
EUVIMED